Global Mumps Vaccine Market Research Report 2022

The MMR vaccine is a vaccine against measles, mumps, and rubella (German measles). The first dose is generally given to children around 9 months to 15 months of age, with a second dose at 15 months to 6 years of age, with at least 4 weeks between the doses.
Due to the COVID-19 pandemic, the global Mumps Vaccine market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Mumps Vaccine market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Mumps Vaccine landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Child accounting for % of the Mumps Vaccine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals Pharmacies segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Mumps Vaccine include MedImmune, Johnson & Johnson, Merck & Co., Inc., Sanofi, Serum Institute of India, Bavarian Nordic, Astellas Pharma India, CSL Limited and Emergent BioSolutions, etc. In terms of revenue, the global 3 largest players have a % market share of Mumps Vaccine in 2021.
This report focuses on Mumps Vaccine volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Mumps Vaccine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and India, etc.
Global Mumps Vaccine Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Child
Adult
Segment by Application
Hospitals Pharmacies
Retail Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
MedImmune
Johnson & Johnson
Merck & Co., Inc.
Sanofi
Serum Institute of India
Bavarian Nordic
Astellas Pharma India
CSL Limited
Emergent BioSolutions
GlaxoSmithKline
Panacea Biotec, Ltd.
Biological E Limited
Bharat Biotech Ltd.
Novavax, Inc.
Novartis
Sinovac Biotech, Ltd.
Incepta Vaccine Limited
Valneva SE
VBI Vaccines
PT Bio Farma